- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT04885114
Safety and Tolerability Study With VY-HTT01, in Adults With Early Manifesting Huntington's Disease
2021년 8월 9일 업데이트: Voyager Therapeutics
A Phase 1B, Open-label, Randomized, Controlled, Multicenter, Dose Escalation Study of the Safety, Tolerability, and Biological Effects of VY-HTT01 Administered Via Intraparenchymal Infusion of the Putamen and Thalamus in Adults With Huntington's Disease
This is the first clinical study of VY-HTT01, a gene therapy for early-stage Huntington's Disease (HD) patients.
The primary goal of this trial is to evaluate the safety and tolerability of VY-HTT01.
This study is a first in human study, Phase 1b, open-label, randomized, multicenter, dose escalation study with a delayed treatment control arm.
연구 개요
상세 설명
This dose escalation trial will evaluate the safety and tolerability of 4 single dose levels of VY-HTT01.
The maximum duration that a subject randomized to treatment may be involved in the study is up to 15 months.
Delayed treatment subjects will be followed for a minimum of 6 months as a control before moving up into the treatment arm in the next cohort.
The maximum duration that a delayed treatment subject may be involved in the study is up to 24 months.
Subjects who participate in this study will be asked to enroll in a long-term observation study.
연구 유형
중재적
단계
- 1단계
참여기준
연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.
자격 기준
공부할 수 있는 나이
18년 이상 (성인, 고령자)
건강한 자원 봉사자를 받아들입니다
아니
연구 대상 성별
모두
설명
Inclusion Criteria:
- Must be at least 18 years old.
- Have CAGn repeat >39.
- Have diagnostic confidence score of 4 based on motor, cognitive, or behavioral symptoms.
- Have a TFC score of 13 to 11.
- Have stable dosing of neurological and psychiatric medications.
- Capable of giving informed consent.
- Able to comply with all procedures and study visits.
Exclusion Criteria:
- Have any significant structural or degenerative neurologic disease other than HD.
- Have any chronic disability, significant systemic illness and/or, unstable medical condition, or clinical findings noted.
- Have primary or secondary immune-compromise due to infections or medical conditions or chronic therapies.
- Have contraindications to lumbar puncture or increased risks of bleeding upon surgery.
- Started or changed dose of a concomitant CNS medication within 30 days.
- Had prior neurosurgical procedures that could complicate the study procedures.
- Have used any investigational therapies within 30 days prior to Screening, oligonucleotide therapies within 9 months prior to Baseline, or any prior gene therapy.
- Male or female with reproductive capacity and is unwilling to use highly effective contraception for 12 months after surgery.
- Have contraindications to MRI such as claustrophobia, embedded metal in the body, or known allergy or intolerance to contrast agents.
공부 계획
이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 순차적 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
실험적: Cohort 1 Unilateral low dose
3.0 x 10^9 (vg/mL) rAAV1-miHHT
|
Single dose MRI guided intraparenchymal infusion of rAAV1 - (mi)RNA HTT.
다른 이름들:
|
실험적: Cohort 2 Bilateral low dose
3.0 x 10^9 (vg/mL) rAAV1-miHHT
|
Single dose MRI guided intraparenchymal infusion of rAAV1 - (mi)RNA HTT.
다른 이름들:
|
실험적: Cohort 3 Bilateral mid dose
1.7 x 10^10 (vg/mL) rAAV1-miHHT
|
Single dose MRI guided intraparenchymal infusion of rAAV1 - (mi)RNA HTT.
다른 이름들:
|
실험적: Cohort 4 Bilateral high dose
9.9 x 10^10 (vg/mL) rAAV1-miHHT
|
Single dose MRI guided intraparenchymal infusion of rAAV1 - (mi)RNA HTT.
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Incidence and type of AEs
기간: Collected for duration of study, average of 1 year after treatment
|
Safety will be assessed by measuring the number and type of AE or SAEs.
|
Collected for duration of study, average of 1 year after treatment
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Level of VY-HTT01 in blood
기간: Collected for duration of study, average of 1 year after treatment
|
Change in baseline of the levels of VY-HTT01 vector genome in blood over time.
|
Collected for duration of study, average of 1 year after treatment
|
Unified Huntington Disease Rating Scale (UHDRS)
기간: Collected for duration of study, average of 1 year after treatment
|
UHDRS will assess changes from baseline in summary scores of motor function, cognitive function, behavioral function, and functional abilities.
UHDRS uses a 5-point ordinal scale ranging from 0-4 with the highest score indicating a more severe (worse) outcome.
|
Collected for duration of study, average of 1 year after treatment
|
Clinical Global Impression (CGI) Measures
기간: Collected for duration of study, average of 1 year after treatment
|
CGI-Global Improvement measure will assess changes from baseline in CGI-Severity of Illness score.
Both CGI-Global Improvement and CGI- Severity measures are based on a 7-point scale, with the highest score indicating a more severe (worse) outcome.
|
Collected for duration of study, average of 1 year after treatment
|
Huntington's Disease Quality of Life (HD-QOL) Measure
기간: Collected for duration of study, average of 1 year after treatment
|
HD-QOL measure will assess changes from baseline in the HD-QOL score using a 40-question scale to identify quality of life in HD.
HD-QOL is based on a 7-point scale of frequency ranging from "never" to "all of the time" with "extreme problems" indicating a more severe (worse) outcome.
|
Collected for duration of study, average of 1 year after treatment
|
EuroQol 5 Dimension 5 Level (EQ-5D-5L) Measure
기간: Collected for duration of study, average of 1 year after treatment
|
EQ-5D-5L measure will assess changes from baseline in the EQ-5D-5L score across 5 domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.
The EQ-5D-5L is scored on a 5-level severity ranking that ranges from "no problems" through "extreme problems", with "extreme problems" indicating a more severe (worse) outcome.
|
Collected for duration of study, average of 1 year after treatment
|
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Magnetic Resistance Imagining (MRI)
기간: Collected for duration of study, average of 1 year after treatment
|
MRI assessments will include whole brain volume, white matter volume, gray matter volume, and ventricular volume, and volumes of the putamen and thalamus covered by VY-HTT01 infusions during surgery.
|
Collected for duration of study, average of 1 year after treatment
|
Levels of HTT protein in CSF
기간: Collected for duration of study, average of 1 year after treatment
|
Change from baseline in levels of HTT protein in CSF (Cerebrospinal fluid) over time.
|
Collected for duration of study, average of 1 year after treatment
|
Levels of HTT protein in blood
기간: Collected for duration of study, average of 1 year after treatment
|
Change from baseline in levels of HTT protein in blood over time.
|
Collected for duration of study, average of 1 year after treatment
|
Huntington's Disease Cognitive Assessment Battery (HD-CAB) Measure
기간: Collected for duration of study, average of 1 year after treatment
|
HD-CAB measure will assess changes from baseline in the HD-CAB score for cognitive dysfunction in early manifest HD patients.
HD-CAB consists of 6 tests; (1) Symbol Digit Modality Test (SDMT), (2) Paced Tapping, (3) One Touch Stockings of Cambridge, (4) Emotional Recognition, (5) Trial Making B and (6) Hopkins Learning Test.
A multi-component score is derived by transforming the subject's score on each cognitive test to a z-score.
The six z-scores are averaged to produce the HD-CAB score.
A positive change from baseline indicates improvement in cognitive function; a negative change indicates worsening in cognitive function.
|
Collected for duration of study, average of 1 year after treatment
|
Level of Neurofilament Light chain (NfL) in CSF
기간: Collected for duration of study, average of 1 year after treatment
|
Change from baseline in levels of NfL in CSF over time.
|
Collected for duration of study, average of 1 year after treatment
|
Level of Neurofilament Light chain (NfL) in blood
기간: Collected for duration of study, average of 1 year after treatment
|
Change from baseline in levels of NfL in blood over time.
|
Collected for duration of study, average of 1 year after treatment
|
공동 작업자 및 조사자
여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.
연구 기록 날짜
이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.
연구 주요 날짜
연구 시작 (예상)
2021년 7월 30일
기본 완료 (예상)
2024년 12월 30일
연구 완료 (예상)
2024년 12월 30일
연구 등록 날짜
최초 제출
2021년 3월 2일
QC 기준을 충족하는 최초 제출
2021년 5월 7일
처음 게시됨 (실제)
2021년 5월 13일
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
2021년 8월 16일
QC 기준을 충족하는 마지막 업데이트 제출
2021년 8월 9일
마지막으로 확인됨
2021년 8월 1일
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .